General Information of Drug (ID: DM0BQYX)

Drug Name
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Drug Info
Synonyms 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol; CHEMBL232067; BDBM50210228
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10093682
TTD Drug ID
DM0BQYX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [2]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [3]
Hydromorphone DMHP21E Back pain ME84.Z Approved [4]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [5]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [6]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [7]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [8]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [9]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [10]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Nociceptin receptor (OPRL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [12]
SER-100 DMDW5ZC Heart failure BD10-BD13 Phase 2 [13]
BTRX-246040 DMA9238 Major depressive disorder 6A70.3 Phase 2 [14]
LY-2940094 DMB5L6Q Major depressive disorder 6A70.3 Phase 2 [15]
NOCICEPTIN DMUPA7C Headache 8A80-8A84 Phase 1 [16]
JTC-801 DMV3UN4 Pain MG30-MG3Z Discontinued in Phase 2 [17]
ND1251 DMMLESX Depression 6A70-6A7Z Discontinued in Phase 1 [18]
ATI-17000 DMZJVR5 Irritable bowel syndrome DD91.0 Preclinical [19]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB Discovery agent N.A. Investigative [20]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Codeine DMJX6ZG Allergic rhinitis CA08.0 Approved [21]
Hydromorphone DMHP21E Back pain ME84.Z Approved [22]
Loperamide DMOJZQ9 Diarrhea ME05.1 Approved [23]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [9]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [24]
Butorphanol DM5KYPJ Pain MG30-MG3Z Approved [21]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [25]
Met-enkephalin DMSZFTP Pain MG30-MG3Z Phase 2 [26]
AZD-2327 DM8FZOG Anxiety disorder 6B00-6B0Z Phase 2 [27]
ADL-5747 DMMUPTN Pain MG30-MG3Z Phase 2 [28]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nalbuphine DMOSQGU Pain MG30-MG3Z Approved [29]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [10]
CHLOROXINE DMFZBMQ Erythema ME64.0 Approved [30]
Difelikefalin DMHZBEO Pruritus EC90 Approved [31]
Dezocine DMJDB0Y Pain MG30-MG3Z Approved [32]
Asimadoline DMND3AB Diarrhea-predominant irritable bowel syndrome DD91.01 Phase 3 [33]
JNJ 67953964 DMJ8Y5N Major depressive disorder 6A70.3 Phase 3 [34]
PHN-131 DM1SV8I Pain MG30-MG3Z Phase 2/3 [35]
CR-845 DMJYTUQ Pain MG30-MG3Z Phase 2/3 [36]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nociceptin receptor (OPRL1) TTNT7K8 OPRX_HUMAN Inhibitor [1]
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Inhibitor [1]
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Inhibitor [1]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Inhibitor [1]

References

1 Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
2 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
3 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
4 Clinical pipeline report, company report or official report of signaturerx.
5 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
6 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
10 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
12 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
13 Clinical pipeline report, company report or official report of Serodus ASA.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.
16 Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41.
17 Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23(2):301-3.
18 The nociceptin receptor as a potential target in drug design. Drug News Perspect. 2001 Aug;14(6):335-45.
19 Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65.
20 Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
21 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
22 Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
23 Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
24 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
25 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
26 Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
27 Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
30 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
31 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
32 Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
33 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
34 Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
35 Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
36 Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.